- Home
- PRT vs ATNM Comparison
PRT vs ATNM Comparison
Compare PRT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | ATNM |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 36.8M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRT | ATNM |
|---|---|---|
| Price | $3.45 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 41.5K | ★ 119.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.47% | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $1.02 |
| 52 Week High | $4.42 | $1.95 |
Technical Indicators
Market Signals| Indicator | PRT | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 50.82 |
| Support Level | $3.28 | $1.02 |
| Resistance Level | $4.09 | $1.71 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 60.00 | 71.11 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.